KURA logo

KURA Kura Oncology, Inc.

NASDAQ · Biotechnology · Healthcare

$6.91
-0.44 (-5.99%)

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapie…

Market Cap: $634.88Mkuraoncology.com

Price

No data yet.

Social Signal Score

58
5d
—
30d
56
6 mentions
—
60d
57
11 mentions
—
90d
60
17 mentions
—
news: 17

Analyst Ratings

17 analysts
Buyconsensus
Strong Buy 0Buy 15Hold 2Sell 0Strong Sell 0
Avg price target$24+247.3%
Low $24Median $24High $24
Current Consensus

Revenue

$22.84M
$0.00$17.96M$35.92M$53.88M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-2.87
$-3.27–$-2.36
8 analysts
FY2026
$-3.20
$-3.46–$-2.98
9 analysts
FY2027
$-2.50
$-3.40–$-1.80
10 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Troy Wilson
Sector
Healthcare
Industry
Biotechnology
Employees
260
Beta
0.38
Country
US
Piotroski score
3 / 9 (Weak)
Altman Z-score
-3.47
kuraoncology.com